Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia

The development of imatinib has revolutionized the treatment of chronic myeloid leukemia. Follow-up analysis of IRIS trial participants continues to demonstrate durable responses for imatinib at 400 mg/day. However, 10%–15% of patients with chronic myeloid leukemia will become imatinib-resistant or...

Descripción completa

Detalles Bibliográficos
Autores principales: DeRemer, David L, Katsanevas, Katerina, Ustun, Celalettin
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085241/
https://www.ncbi.nlm.nih.gov/pubmed/21556318
http://dx.doi.org/10.2147/CMR.S11948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085241/
https://www.ncbi.nlm.nih.gov/pubmed/21556318
http://dx.doi.org/10.2147/CMR.S11948

Ejemplares similares